Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia.

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biomarker Discovery

Background:

• Preeclampsia is a significant global cause of maternal and neonatal mortality.
• Current diagnostic methods for preeclampsia rely on nonspecific clinical signs and symptoms.
• Earlier diagnosis of preeclampsia could lead to improved patient prognosis.

Purpose of the Study:

• To review the role of angiogenic factors in preeclampsia pathogenesis.
• To explore the utility of angiogenic biomarkers for preeclampsia risk stratification.
• To evaluate angiogenic biomarkers for diagnosis and prognosis of preeclampsia.

Main Methods:

• Literature review focusing on angiogenic factors in preeclampsia.
• Analysis of studies investigating angiogenic factors for prediction.
• Synthesis of evidence on biomarker use in clinical practice.

Main Results:

• Preeclampsia involves abnormal placentation, angiogenic imbalance, and endothelial dysfunction.
• Circulating levels of specific angiogenic factors change weeks before preeclampsia onset.
• Angiogenic factors show potential for predicting preeclampsia and adverse outcomes.

Conclusions:

• Angiogenic factors are implicated in the pathogenesis of preeclampsia.
• Angiogenic biomarkers offer promise for earlier and more accurate preeclampsia diagnosis.
• Biomarker-guided risk stratification may improve management and outcomes for preeclampsia.